Search IDYA
IDEAYA Biosciences, Inc.
Nasdaq · CIK 1676725
Last close37.36
Daily change-0.45 (-1.19%)
10 Years gain+233.87%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IDYA · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
55.3Momentum
n/aAcceleration
n/aConfidence
69.0Annual Revenue7
Quarterly Revenue19
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM1,827.57%OK
Revenue CAGR 3Y62.54%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $218.71M | $218.71M | -$159.31M | -$71.10M | -$73.47M | 100% | -72.84% | -33.59% | -32.84% | 88.49M |
| 2025 FY Dec 31, 2024 | $7.00M | $7.00M | -$326.98M | -$247.58M | -$251.44M | 100% | -4,671.07% | -3,592.01% | -107.9% | 81.68M |
| 2025 FY Dec 31, 2023 | $23.39M | $23.39M | -$134.43M | -$115.22M | -$117.59M | 100% | -574.85% | -502.85% | -263.51% | 57.52M |
| 2024 FY Dec 31, 2022 | $50.93M | $50.93M | -$62.50M | -$87.18M | -$90.62M | 100% | -122.72% | -177.92% | -250.83% | 41.44M |
| 2023 FY Dec 31, 2021 | $27.94M | $27.94M | -$50.27M | -$55.78M | -$58.42M | 100% | -179.91% | -209.09% | n/a | 35.25M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $223.25M | sum latest 4 fiscal quarters Revenue | OK | 0000950170-24-120675, 0001193125-25-264632 |
| Revenue Growth TTM | 1,827.57% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000950170-24-120675, 0001193125-25-264632 |
| Revenue CAGR 3Y | 62.54% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-054533 |
| Revenue CAGR 5Y | 62.11% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-054533 |
| Gross Profit CAGR 3Y | 62.54% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-054533 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332774 |
| Current Ratio | 10.45x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.43 | Revenue / Diluted Shares | OK | 0000950170-24-120675, 0001193125-25-264632 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-054533 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001193125-26-332774 |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |